693285-71-1

Basic information

• Product Name: 4-BROMO-3-ISOPROPYL-1H-INDAZOLE
• Synonyms: 4-BROMO-3-ISOPROPYL-1H-INDAZOLE;1H-Indazole, 4-broMo-3-(1-Methylethyl)-
• CAS NO: 693285-71-1
• Molecular Formula: C10H11BrN2
• Molecular Weight: 0
• Mol File: 693285-71-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-BROMO-3-ISOPROPYL-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3-ISOPROPYL-1H-INDAZOLE(693285-71-1)
• EPA Substance Registry System: 4-BROMO-3-ISOPROPYL-1H-INDAZOLE(693285-71-1)

Safety Data

• Hazardous Substances Data: 693285-71-1(Hazardous Substances Data)

Upstream product

• 360575-28-6 2-bromo-6-fluorobenzaldehyde 
• 1073-06-9 3-fluorobromobenzene 
• 97-72-3 2-Methylpropionic anhydride 
• 693285-70-0 1-(2-bromo-6-fluoro-phenyl)-2-methyl-propan-1-one 

Downstream Products

• 1384542-75-9 2-(tert-butylamino)-4-(3-isopropyl-4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-1H-indazol-1-yl)benzonitrile 
• 1384542-20-4 2-(tert-butylamino)-4-(3-isopropyl-4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-1H-indazol-1-yl)benzamide 
• 1384542-85-1 4-(3-isopropyl-4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-1H-indazol-1-yl)-3-nitrobenzonitrile 
• 1384542-86-2 3-amino-4-(3-isopropyl-4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-1H-indazol-1-yl)benzonitrile 
• 1384542-87-3 4-(3-isopropyl-4-(4-(pyridin-3-yl)-1H-imidazol-1-yl)-1H-indazol-1-yl)-3-(isopropylamino)benzonitrile 

Relevant articles and documents

NOVEL INDOLE OR INDAZOLE DERIVATIVE OR SALT THEREOF

The present invention relates to provision of a novel indazole compound which is capable of inhibiting HSP90 and shows a cytostatic effect on cancer cells. The present invention also relates to provision of a drug useful for preventing and/or treating, on the basis of an HSP90 inhibitory effect, a disease in which HSP90 participates, in particular, cancer. A compound represented by the general formula (I) or a salt thereof: wherein X represents CH or N;any one or two of Y1, Y2, Y3, and Y4 represent C—R3 or N, and the others represent CH;A and B are the same or different and represent an optionally substituted monocyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O;R1 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.;R2 represents a hydrogen atom, a halogen atom etc.;R3 represents a hydrogen atom, a halogen atom etc.;R4 and R5 are the same or different and represent a hydroxyl group etc.;R6 and R7 are the same or different and represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms etc.; andR8 represents an optionally substituted cycloalkyl group having 3 to 7 carbon atoms etc.

3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES

The present invention provides compounds of Formula (I) or (II) salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for example, arthritis, cancer, cardiovascular disorders, skin disorders, inflammation or allergic conditions.

1-ARYL-4-SUBSTITUTED ISOQUINOLINES

1-Aryl-4-substituted isoquinolines analogues of Formula (I) and Formula (II) are provided, as follows : wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) and (II) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 1-aryl-4-substituted isoquinolines, which are useful as probes for the localization of C5a receptors.

4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES

4,5-disubstituted-2-arylpyrimidines of Formula (I) and Formula (II) are provided: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.

3-SUBSTITUTED-6-ARYL PYRIDINES

3-substituted-6-aryl pyridines of Formula (I) are provided: Formula (I) wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula (I) bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.